Euglisemic diabetic ketoacidotic coma caused by dapagliflozin

Ünlüsoy, 2018, Diyabet Tedavisinde SGLT2 İnhibitörleri, Fabad J Pharm Sci, 43, 67 Ogawa, 2016, Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors, J Diabetes Investig, 7, 135, 10.1111/jdi.12401 Traynor, 2014, Dapagliflozin approved for type 2 diabetes, Am J Health Syst Pharm, 71, 263 Meyer, 2018, SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and Australian spontaneous adverse event notifications, Diabetes Care, 41, e47, 10.2337/dc17-1721 Brown, 2018, Euglycemic diabetic ketoacidosis secondary to dapagliflozin use: a case report, J Emerg Med, 54, 109, 10.1016/j.jemermed.2017.10.001 Madaan, 2016, Sodium glucose cotransporter 2 (SGLT2) inhibitors: current status and future perspective, Eur J Pharm Sci, 93, 244, 10.1016/j.ejps.2016.08.025 Katz, 2015, The role of the kidney and SGLT2 inhibitors in type 2 diabetes, Can J Diabetes, 39, 167, 10.1016/j.jcjd.2015.09.001 Kitabchi, 2009, Hyperglycemic crises in adult patients with diabetes, Diabetes Care, 32, 1335, 10.2337/dc09-9032 Chico, 2008, Normoglycemic diabetic ketoacidosis in pregnancy, J Perinatol, 28, 310, 10.1038/sj.jp.7211921 Prater, 2015, Euglycemic diabetic ketoacidosis with acute pancreatitis in a patient not known to have diabetes, Endocr Pract, 1, e88 Abdin, 2016, Euglycemic diabetic ketoacidosis in a patient with cocaine intoxication, Case Rep Crit Care Modi, 2017, Euglycemic diabetic ketoacidosis, Curr Diabetes Rev, 13, 315, 10.2174/1573399812666160421121307 Gelaye, 2016, Severe ketoacidosis associated with canagliflozin (Invokana): a safety concern, Case Rep Crit Care, 2016 Rosenstock, 2015, Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors, Diabetes Care, 38, 1638, 10.2337/dc15-1380